Lithium Treatment Extension for People With Parkinson's Disease
Tests lithium aspartate in people with Parkinson's disease who finished an earlier lithium study.
Plain-language title generated from the registry record
Registry title: Lithium for Parkinson's: an Extension Trial
Key facts
- Where
- Williamsville, United StatesSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 80 years old?
Source: NCT06592014, who can take part
Where in United States
- UBMD NeurologyWilliamsville, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- State University of New York at Buffalo
- Trial code
- NCT06592014
- Record updated
- 26 October 2026
- Original description
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.Read full original descriptionShow less
Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: an Open-label Extension Trial.
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.
All PD patients completing STUDY00007253 or STUDY00008239 at the University at Buffalo will be eligible; No unstable cardiac, medical, neurologic or psychiatric condition in the opinion of the PI; No current use of illicit drugs or current alcohol abuse in the opinion of the PI; No history of brain surgery or possible need for brain surgery including deep brain stimulation (DBS) for at least 24 weeks in the opinion of the PI; Women with child bearing potential will need a negative pregnancy test and not be nursing an infant at screening. Women with child bearing potential will need to report using barrier method or hormonal contraception; Willing and able to sign informed consent and follow study procedures.